Microbot Medical Inc. short interest in 2021
In 2021, Microbot Medical Inc.'s disclosed short interest ran from 8.10% of shares outstanding on 15 Jan 2021 to 1.21% on 15 Dec 2021, a change of -6.89 percentage points. The year's high was 8.16% on 29 Jan 2021 and its low 1.07% on 15 Nov 2021, averaging 4.01% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.37 days on 30 Jul 2021. Full history: Microbot Medical Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 8.10% (15 Jan 2021)
- End of year
- 1.21% (15 Dec 2021)
- Change
- -6.89 pp
- High
- 8.16% (29 Jan 2021)
- Low
- 1.07% (15 Nov 2021)
- Average
- 4.01%
- Highest days to cover
- 7.37 (30 Jul 2021)
- SEC filings marked
- 4
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 8.10% | 2.20 | |
| 29 Jan 2021 | 8.16% | 2.11 | |
| 12 Feb 2021 | 7.34% | 3.57 | |
| 26 Feb 2021 | 6.45% | 3.19 | |
| 15 Mar 2021 | 6.28% | 4.24 | |
| 31 Mar 2021 | 5.17% | 5.48 | 10-K filed |
| 15 Apr 2021 | 4.70% | 4.71 | |
| 30 Apr 2021 | 5.01% | 4.24 | |
| 14 May 2021 | 5.06% | 4.36 | |
| 28 May 2021 | 4.36% | 4.60 | 10-Q filed |
| 15 Jun 2021 | 4.12% | 3.13 | |
| 30 Jun 2021 | 4.10% | 2.06 | |
| 15 Jul 2021 | 3.66% | 3.70 | |
| 30 Jul 2021 | 3.24% | 7.37 | |
| 13 Aug 2021 | 2.92% | 5.02 | |
| 31 Aug 2021 | 2.70% | 1.95 | 10-Q filed |
| 15 Sep 2021 | 2.49% | 4.01 | |
| 30 Sep 2021 | 2.11% | 5.15 | |
| 15 Oct 2021 | 1.36% | 1.72 | |
| 29 Oct 2021 | 1.31% | 4.54 | |
| 15 Nov 2021 | 1.07% | 2.41 | 10-Q filed |
| 30 Nov 2021 | 1.26% | 1.51 | |
| 15 Dec 2021 | 1.21% | 1.89 |
See also: Microbot Medical Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.